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Abstract 
 
Context 
End-of-life policy reforms are being debated in many countries. International evidence is used to 
support different hypothesis about the effects of policy change on end-of-life practices. It is 
unclear whether reliable international comparisons can be made between policy contexts of 
prohibition and legalization. 
 
Objectives 
To assess the potential for comparisons between end-of-life practices across different policy 
contexts. 
 
Methods 
We conducted a scoping review of studies on medical end-of-life practices. We built developed a 
descriptive classification of end-of-life practices that distinguishes practices according to their 
legal status. We focused our review on the intentional use of lethal drugs by physicians, because 
of variations in the legal status of this practice across jurisdictions. MEDLINE, EMBASE, 
CINAHL, and Google Scholar searches were supplemented by expert consultation and hand-
searching of reference lists. The sensitivity of the search strategy was tested using a set of 77 
articles meeting our inclusion criteria. Two research assistants extracted data on end-of-life 
practice definitions and labeling, study methods, and comparisons across policy contexts. 
Canadian decision-makers were involved at different stages of the review to increase its policy 
relevance. 
 
Results 
333 empirical studies on the intentional use of lethal drugs by physicians were identified, 
including data from 19 countries. The bibliographic search captured 76 of the 77 studies initially 
identified studies as meeting the inclusion criteria (sensitivity=98.7%). Studies on the frequency 
of lethal drug use were conducted in jurisdictions with permissive (61.7%) and restrictive 
policies (43.3%). The most common study objectives related to the frequency of end-of-life 
practices, determinants of practices, and conformity with regulatory standards. Large variations 
in definitions and research methods were noted across studies. The use of a descriptive 
classification of end-of-life practices was useful to deal with international variations in 
definitions and labeling. A few international studies compared end-of-life practice in countries 
with different policies, using consistent research methods. We identified no systematic review 
comparing international end-of-life practices in different policy contexts. 
 
Conclusions 
A growing number of empirical studies have assessed medical end-of-life practices in the context 
of prohibition and legalization. The use of a descriptive classification is helpful to distinguish 
practices with different legal status and to deal with international variations in definitions and 
labeling. A systematic review of international evidence is needed to assess the impact of end-of-
life policies on medical practice.   
Introduction 
 
End-of-life policy reforms are being debated in many countries. In Canada, the Criminal 
Code prohibition on the intentional use of lethal drugs by physicians is currently being 
challenged in court1, and in parliament2. In the United States, several referendums and 
policy proposals were recently held on “right to die” legislation3. Similar legislative 
reforms have been debated in France4, and the United Kingdom5. These developments 
create strong pressure on governments and challenge existing end-of-life policies. 
 
Different assumptions are made about the potential effects of policy change on end-of-
life practices. The “slippery slope hypothesis” hold that legalization of certain medical 
end-of-life practices could lead over time to a broadening application of proposed legal 
norms, leading to undesirable consequences on vulnerable patients6-9.  Conversely, the 
“transparency hypothesis” hold that legalization could lead to more open and regulated 
medical practices, thus resulting in better respect of proposed safeguards 10-13. 
 
International evidence is being used in support of these different hypotheses by 
proponents and opponents of policy reforms. For example, Canadian court documents 
and policy proposals included an extensive discussion of international evidence to 
support their position 1,10,14,15. Similarly, the House of Lords in the United Kingdom 
included a lengthy review of international experiences 5, as did the recent Sicard report 
in France 4.  
 
It is unclear whether reliable international comparisons can be made from evidence 
collected in different legal contexts. For example, the feasibility of documenting medical 
practices that are prohibited could be problematic and limit the ability to test the impact 
of policy change. Also, interpreting international evidence is far from straightforward, 
because of potential variations in definitions and classifications of end-of-life practices, 
study methods, health system characteristics and regulation.  
 
As a first step toward the completion of a full systematic review, we sought to map 
available international evidence on medical end-of-life practices, and to assess the 
potential for reliable international comparisons across different policy contexts. Mapping 
available evidence is important to clarify what can realistically be expected from existing 
studies, and to identify current gaps in research. Our review focused on two core 
research questions: 1) what empirical evidence is available on medical end-of-life 
practices in contexts of prohibition and legalization; 2) what is the potential and what are 
the limitations of the empirical evidence to compare the frequency of medical end-of-life 
practices in different legal contexts? 
 
Methods: 
Design 
We conducted a scoping review of studies on medical end-of-life practices, with a focus 
on practices whose legal status differ across jurisdictions (described below). Scoping 
reviews aim at mapping the main sources and types of evidence available in a field of 
interest16. Scoping studies are especially best suited for complex areas of research, and 
can be useful to determine gaps in the existing literature and assess the value of 
conducting a full systematic review.  
Classification of medical end-of-life practices and scoping review focus 
Legal definitions and classifications of medical end-of-life practices vary, and no consensus 
exists at the international level17. For example, definitions of terms like “euthanasia” have 
evolved over time and across countries18-20. In preparation for the scoping review, we developed 
a descriptive classification of end-of-life practices that: 1) distinguishes medical practices 
according to their legal status; 2) is related to observable practices that can be studied 
empirically; and 3) allows for the potential translation of different end-of-life practice definitions 
into comparable categories across countries. 
 
Our descriptive classification distinguishes between: 
1. Withdrawing or withholding of treatments that have the potential to prolong life (e.g. 
cessation of an artificial respiratorventilator, not initiating chemotherapy to for a patient 
with cancer, stopping antibiotics for a patient with pneumonia); 
2. Use of a drug justifiable by its specific effect on symptom management or treatment of a 
health condition, even if an unintended side-effect may be to shorten life  (e.g. 
thrombolysis for myocardial infarction, chemotherapy for cancer, use of opiates adjusted 
titrated to pain control, use of specific sedative medication adjusted titrated to refractory 
symptom control by reduction in patient consciousness21);  
3. Intentional use (prescription, advice, supply, or administration) of a lethal drug that is not 
justified by a specific effect on symptom control or treatment of a medical condition (e.g. 
injection of a neuromuscular blocker without respiratory support, injection of potassium 
chloride to a patient with a normal potassium level, injection of a massive dose of opiates 
above what is necessary for pain control, continuous use of sedatives without artificial 
hydration above what is needed for symptom control).  
 
We emphasize that this classification seeks to distinguish practices according to their legal status 
in different jurisdictions, rather than their ethical or deontological justification. For example, 
some ethicists contest the distinction between withdrawing life-sustaining treatment, using drugs 
whose unintended side-effect may be to shorten life, and the intentional use of lethal drugs22,23. 
However, these practices currently have different legal status in many jurisdictions17.  
 
We should also highlight that, while category #3 refers to the intentional use of lethal drugs that 
is “not justified” by a specific effect on symptom control or treatment of a medical condition, 
this does not mean that no other legal justification can exist for this practice. While many 
jurisdictions prohibit the intentional use of lethal drugs by physicians (e.g. Canada, United-
Kingdom, France, New Zealand), other jurisdictions recognize specific circumstances in which 
such practice can be legally justified. Legal conditions for the intentional use of lethal drugs vary 
across jurisdictions, and can include one or many of the following criteria (this is not an 
exhaustive list): 
 Voluntary request by a competent patient (e.g. Oregon, Vermont, Montana, Washington, 
Belgium, Luxemburg, Netherlands, Switzerland) 17,24,25; 
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 Presence of an advanced directive by a previously competent patient (e.g. Netherlands, 
Belgium, Luxemburg) 19,26,27; 
 Presence of a substituted request in the case of an incompetent patient (e.g. Netherlands) 
8,28,29 
 Presence of unbearable suffering (e.g. Netherlands, Belgium, Luxemburg)17; 
 Presence of a terminal illness with limited life expectancy (e.g. Oregon, Vermont, 
Washington); 
 The self-administration of lethal drugs by the patient himself (e.g. Oregon, Vermont, 
Montana, Washington, Switzerland); 
 The absence of self-interest by the person providing lethal drugs (e.g. Switzerland)30. 
 
To reflect these differences in end-of-life policies across jurisdictions, our descriptive 
classification further distinguishes if the intentional use of a lethal drug is carried out: a) with a 
voluntary and informed request made by the patient prior to death; b) if a voluntary advanced 
directive was made by a previously competent patient, c) if a substitute request was made by the 
proxy decision-maker of an incompetent patient, or d) if the medical practice is carried without a 
patient or substitute request. We also distinguish when a lethal drug is administered by the 
patient himself or by someone else.  
 
As illustrated in Table 1, the descriptive classification distinguishes end-of-life practices that 
have different legal statuses across jurisdictions. To yield a manageable number of studies, we 
focused the scoping review on the intentional use of lethal drugs not justified by a specific effect 
on symptom control or treatment of a health condition (category #3 of the descriptive 
classification). This choice was justified by variation in the legal status of this practice across 
different jurisdictions. 
Data sources and search strategy 
We conducted two bibliographic searches sequentially. First, we ran an open search strategy in 
Google Scholar using the search terms “end-of-life decisions”, “euthanasia”, “assisted suicide”, 
“assisted dying”, “assisted death”, “assisted dying”, “medical aid in dying”, “termination of life”, 
“medical behaviors that shorten life”. This was supplemented with hand searching of reference 
lists and expert consultation. This initial search identified a set of studies meeting our inclusion 
criteria, which were used to develop and test a more focused search strategy in electronic 
databases. Our final search strategy was run in March 2012 in three electronic databases 
(MEDLINE, EMBASE, and CINAHL) using the search terms listed in Appendix 1.  
Inclusion and exclusion criteria 
The scoping review proceeded in two stages, with a progressive restriction of the inclusion 
criteria between each stage. In Stage 1 (mapping of the topic area), we included all empirical 
qualitative or quantitative studies on the use of lethal drugs by physicians with data on actual 
medical practices. We excluded studies on physicians’ attitudes and opinions, studies on the use 
of lethal drugs without physician involvement (e.g. injection by a nurse without a physician’s 
prescription), or studies on lethal drug use outside the medical context (e.g. prisoner execution). 
We also excluded studies without an abstract, animal studies and those published in a language 
other than English or French. In Stage 2 (comparability of international frequency studies), we 
further restricted our analysis to quantitative studies on the frequency of physicians’ lethal use of 
drugs. Two research assistants screened each reference against the inclusion and exclusion 
criteria. Disagreements were resolved through team discussion with the principal investigator 
(AB).  
Data extraction 
We extracted data on study methods (design, objectives, country, year of data collection, 
sampling strategy, source of data collection, data collection method, number of participants and 
response rate, respondents), on how medical practices were defined and measured (definitions, 
question wording, type of drugs used, and assessment of its lethal potential), and on the presence 
of comparisons within and across jurisdictions with different policies. Data extraction was 
conducted by two research assistants using a structured extraction sheet. Extracted data were 
imported in a FilemakerPro database developed with the help of an information technology 
specialist.  
Data analysis 
In stage 1, we used content analysis to map the main study objectives of all empirical studies on 
the use of lethal drugs by physicians. Key themes were charted and analyzed using the theory of 
planned behavior as an original template31. In Stage 2, we used descriptive statistics to report on 
the main characteristics of frequency studies, seeking to identify the main sources of 
heterogeneity and the potential for conducting international comparisons. We classified the 
policy context as “permissive” when the intentional use of lethal drugs was allowed by public 
policies at the time of the study (e.g. Belgium after 200219, Oregon after 199725) and “restrictive” 
when the intentional use of lethal drugs was prohibited by public policies. 
Integrated knowledge translation strategy 
We followed an integrated knowledge translation strategy to increase the policy relevance of the 
review32. We set up an advisory committee composed of key medical, legal, governmental, and 
public organizations involved in end-of-life policymaking in Canada, including organizations 
with different views on end-of-life policies. Two one day meetings were organized over a one 
year period: the first meeting focused on agreeing roles and responsibilities, discussing scoping 
review objectives, and discussing the descriptive classification of end-of-life practices; and the 
second meeting aimed at reviewing preliminary findings and identify priorities for further 
research. While the advisory committee’s recommendations informed research decisions, the 
researchers remained ultimately responsible for the scientific integrity of the review. 
 
Results: 
Identified studies 
 
Figure 1 describes the flow of included studies. 1308 unique abstracts were screened, yielding a 
total of 333 empirical studies on the use of lethal drugs by physicians published between 1998 
and 2012 (Table 2). Our final bibliographic search captured 76 of the 77 initially identified 
studies meeting the inclusion criteria (sensitivity=98.7%), meaning that our search strategy was 
highly sensitive to capturing empirical studies on the use of lethal drugs by physicians. Most 
studies (N=248, 74.4%) used quantitative research designs. 
 
Table 3 includes the main study objectives covered by the 333 empirical studies on the use of 
lethal drugs by physicians. The most frequent study objectives related to determinants of requests 
and practices (N=64, 19.2%), frequency of lethal drug use (N=60, 18.0%), and conformity of 
practices with regulatory standards (N=48, 14.4%). We identified few empirical studies on 
medical complications of lethal drug use (N=6, 1.8%) and their impact on relatives (N=8, 2.4%).  
 
Sixty quantitative articles aimed at assessing the frequency of lethal drug use, and these articles 
were analyzed in more detail to assess their potential for international comparisons (Table 4). 
There was a large clustering of articles from a few countries, with multiple articles reporting 
results of the same study. For example, 6 large cross-sectional surveys conducted in the 
Netherlands, Belgium, Denmark, Italy, Sweden, and Switzerland accounted for 45% (N=27) of 
all articles on the frequency of lethal drug use by physicians. While all articles reported data on 
the intentional use of lethal drugs by physicians (as per the inclusion criteria), other end-of-life 
practices were also reported in these studies, including the use of drugs justified by symptom 
control (N=24, 40.0% of articles) and the withholding/withdrawal of life-sustaining treatment 
(N=29, 48.3%). Only 58% (N=35) of studies included data on the use of lethal drugs without 
patient request. 
Labelling, definitions, and classification of medical end-of-life practices 
Among the 60 quantitative articles on the frequency of end-of-life practices, there were large 
variations in terms of labeling, definitions, and classifications of medical end-of-life practices. In 
33% of articles (N=20), no definitions of different end-of-life practices were included. When 
definitions were provided, similar labels were found to have different meanings across studies, 
countries, and over time. For example, some studies used “euthanasia” to refer to the 
administration of lethal drugs by physicians, without distinguishing if this was carried with or 
without voluntary patient request33. Other studies had more restrictive definitions, and used 
“euthanasia” to refer to the intentional administration of a lethal drug with a patient request34-36. 
Other labels used to refer to the intentional use of lethal drugs by physicians included “physician 
assisted dying”37, “physician assisted suicide”38, “help to die”39, “ending of life”40, “life-
terminating act”41, and “using drugs to end life”42. 
 
Wording of study questionnaires varied across studies, and 25% of articles (N=15) did not 
provide information about how questions were framed. Some questions made it difficult to 
distinguish between the intentional use of lethal drugs and treatment withholding/withdrawal 
(e.g. “Have you ever taken deliberate action that would directly cause a patient’s death?”43). 
Other differences in questions related to the framing of physicians’ intentions, which was 
sometimes described as ending the patient’s life 38,44-46, bringing about the patient’s death 47, 
hastening the patient’s death 28,48,49, or shortening the patient’s life13.  
 
Distinguishing between practices with different legal statuses was sometimes difficult because of 
inconsistencies between empirical practice studies and public policies. For example, the Belgian 
Euthanasia Act of 2002 defines euthanasia as the “intentional life-terminating action by someone 
other than the person concerned, at the request of the latter”19. However, empirical studies from 
Belgium and other European countries exclude from the euthanasia category all use of lethal 
drugs with a “partial” intention to hasten death35,49, a distinction that is not reflected in public 
policies. This means that some practices that meet the legal definition of euthanasia would not be 
classified as such in those empirical studies. Other examples of inconsistencies include grouping 
together the frequency of lethal drug use in children and adults13,35,49, despite the fact that 
policies in the studied countries have different legal provisions for lethal drug use in these age 
categories.  The grouping of practices with mixed legal statuses was most problematic with 
categories labeled as  “intensification of symptom alleviation”, “terminal sedation” and 
“continuous deep sedation” 50-52. Proper analysis of these categories is complex because of 
incomplete outcome reporting53 and discrepancies between the reporting of the same studies in 
different languages40,54. 
 
A related but distinct problem is the absence of information on the actual lethal potential of drugs 
used by physicians. Only 33% of studies (N=20) reported data on the type of drugs used, and 8% 
(N=5) appraised their actual lethal potential by external experts. This means that observed 
differences between countries could simply reflect physicians’ subjective reporting of their 
intentions rather than changes in actual practices (e.g. what drugs are used, at what dose 
initiation/escalation, and with what lethal potential). This limitation is important given the fact 
that intentions have been found imperfect to predict end-of-life practices54 and because up to 
76% of drugs used by physicians with the intention to cause death have low lethal potential55. 
While the problem of end-of-life categories with mixed legal status would tend to underestimate 
the frequency of intentional lethal drug use by physicians, absence of data on drug lethality 
would tend to over-estimate the frequency of physicians’ practices that actually cause patients’ 
deaths.  
Potential for international comparisons of end-of-life practice frequencies 
Studies on the frequency of lethal drug use by physicians were conducted in countries with 
permissive (N=37, 61.7%) and restrictive policies (N=26, 43.3%)1, thus offering some potential 
for international comparisons. All frequency studies used cross-sectional study designs, some 
with repeated measurement over time and across countries . Twenty-seven percent of articles 
(N=16) included comparison of end-of-life practice frequencies before and after a change in 
public policies (e.g. before and after the adoption of the 2002 Euthanasia Act in Belgium)34,56, 
and 28.3% (N=17) included comparisons across countries with different policies (e.g. 
comparison between different European countries)35,57,58.  
 
A number of differences in sampling strategy, data collection methods, and outcome measures 
were noted, all of which could influence comparisons of end-of-life practice frequencies. Data on 
end-of-life practices were mostly collected from physicians’ self-administered questionnaires 
(N=44, 72.3%), individual interviews (N=13, 21.7%) , or physicians’ self-reporting to external 
authorities (N=5, 8.3%) . Data were most often collected retrospectively, with professionals 
being asked to recall a death they had attended. In Only in rare cases were end-of-life practice 
data collected prospectively59.  
 
Response rates varied significantly across studies, ranging from 34% to 91%. Some countries 
with restrictive policies on lethal drug use had higher response rates than permissive countries, 
suggesting that variables other than the legal status of end-of-life practices influenced 
respondents 35,57. Response rates varied according to country, the data collection method, and the 
strategy used to ensure respondents’ anonymity.  
 
Three main patterns of sampling methods and outcome measures were identified:  
                                                 
1 These two categories are not mutually exclusive. 
1. Half of the identified articles were based on stratified samples of death certificates. These 
studies reported the frequencies of medical practices in relation to the percentage of all 
annual deaths13,35,40,49,56.  
2. A second group of studies used similar outcome measures (% of all annual deaths), but a 
different sampling method based on professional registries36,59-62.  
3. A third group of studies used sampling methods and outcome measures based on the total 
number of physicians (eg. proportion of physicians who reported ever having 
intentionally used a lethal drug in their career)33,58.  
 
Some studies focused on the frequency of lethal drug use in specific populations (e.g. 
children)28,57 and among specific professional groups (e.g. general practitioners)61. A few studies 
aimed sought to provideat providing national frequency estimates, but specifically excluded end-
of-life practices in children 13,35,49,50,52,56,63. These exclusions could limit the comparability of 
frequency estimates across studies addressing different sub-populations. 
 
We identified a number of empirical studies that used consistent methodologies to compare end-
of-life practice frequencies in different countries, and to assess changes of practices over time. 
One example is the EURELD research consortium funded by the European Commission, which 
conducted two international studies of medical end-of-life practices in 2001 and 2002. The 2001 
EURELD study used nationally representative sample of death certificates to compare the annual 
frequency of medical end-of-life practices in 6 European countries with different legislative 
frameworks (Netherlands, Belgium, Switzerland, Sweden, Italy, and Denmark)35,50,52. The 2002 
EURELD study used a random sample of physicians to compare the lifetime prevalence of end-
of-life practices in 7 countries in Europe and Australia58. National surveys conducted in the 
Netherlands (1990, 1995, 2001, 2005, 2010)34,40,59,64,65, Belgium (1998, 2001, 2007)13,49,56 and 
France (2009)63 used similar sampling strategies and questionnaires than the 2001 EURELD 
study2. 
 
We found no systematic review of international evidence about the effects of public policies on 
end-of-life practices. A few published reviews have assessed changes in medical practices in 
selected countries (e.g. the Netherlands, Belgium, and the USA6,34,66,67) or on specific 
populations68.  
 
Discussion 
To the best of our knowledge, this is the first rigorous scoping review to assess the potential for 
reliable end-of-life practice comparisons between end-of-life practices across different policy 
contexts. Our findings indicate that it is feasible to conduct studies on end-of-life practices in the 
context of legalization and prohibition, as demonstrated by the number of studies on the 
intentional use of lethal drugs by physicians in countries where this practice is authorized, and in 
those where it remains prohibited.  
 
This review documents an important growth in international empirical evidence on end-of-life 
practices in the past 25 years. We identified a substantial number of studies that used consistent 
                                                 
2 The 2001 Dutch and Belgium national surveys were conducted as part of the 2001 EURELD 
consortium study. 
methods to compare end-of-life practice frequencies in different policy contexts, thus supporting 
the need and potential for a full systematic review on this topic. Another important contribution 
of this review is the development of a descriptive classification of end-of-life practices, which 
helps address differences in labels and definitions across studies, and facilitates the distinction of 
practices with different legal status. Such descriptive classification could be implemented in a 
full systematic review of international evidence. 
 
This scoping review also brings greater clarity regarding the main methodological challenges for 
making reliable international comparisons.  Heterogeneity in sampling strategy, data collection 
methods, and outcome measures limits the potential for valid comparisons between many 
studies. Dealing with low response rates is another challenge, particularly when non-response 
differentially affects a specific policy context. Most studies estimate the frequency of end-of-life 
practices based only on physicians’ reported intentions, without details of which behaviors were 
actually performed and what their lethal potential is. Finally, the fact that available studies are 
observational in nature, with a limited number of measures before and after policy reform, is 
likely to limit, but not entirely prevent, the ability to attribute changes in end-of-life practices to 
public policies or to other contextual factors (e.g. health system characteristics, cultural attitudes, 
and professional norms). Thus, rigorous quality assessment of included studies is essential in any 
future systematic review of international evidence. 
Policy implications 
The main implication from this scoping review is that policymakers should be careful in drawing 
straightforward conclusions about the effects of different end-of-life policies. While empirical 
studies are frequently quoted in public and policy debates, acknowledgement of the 
heterogeneity of study methods, risks of biased frequency estimates, and relevance to the 
particular context is rarely discussed. Failure to recognize these limitations could lead to 
inappropriate conclusions by policymakers and the public. Policymakers should prioritize robust 
systematic reviews of empirical evidence rather than selected analysis of single studies to assess 
what is known and unknown of policy effects. To reduce as much as possible the above 
problems of misinterpretation of findings and to contextualize appropriately the available 
international evidence, greater collaboration between research teams, decision-makers and policy 
experts would be highly recommended.. 
Study strengths and limitations and directions for future research 
A strength of this scoping review is that it reveals the range of empirical evidence available from 
different policy contexts. Testing of our search strategy on a large set of studies initially 
identified as meeting the study inclusion criteria showed that it was highly sensitive to 
identifying empirical studies on the intentional use of lethal drugs by physicians. The 
comprehensiveness of our review may however have been hampered by its focus on medical 
databases and the screening of frequency studies based on published abstracts alone. Also, 
scoping reviews focus on breath of coverage, rather than depth of analysis16, and so we neither 
conducted a systematic quality assessment of included studies, nor did we synthesize study 
results. This review nonetheless represents a valuable preliminary step toward the completion of 
a full systematic review of international comparative evidence, by: 1) documenting the feasibility 
of comparing similar end-of-life practices in different legal contexts; 2) identifying a set of 
international studies comparing end-of-life practices using consistent research methods; 3) 
developing a descriptive classification of end-of-life practices to address international variations 
in definitions and labels; 4) highlighting the main methodological challenges that should be 
taken into account in quality assessment of comparative studies.  
 
Conclusion 
A growing number of empirical studies have assessed medical end-of-life practices in different 
policy contexts (prohibition and legalization), using consistent methods, thus offering some 
potential for reliable international comparisons. The use of a descriptive classification of end-of-
life practices is helpful to distinguish practices with different legal status, and to deal with 
international variations in definitions and labeling. A better understanding of the strengths and 
limitations in end-of-life practice studies is key for providing policy guidance that is both 
context-sensitive and informed by an international set of evidence. A systematic review of 
international evidence is needed to assess the impact of end-of-life policies on medical practice, 
and thereby  contribute meaningfully to policymaking.  
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sur l’euthanasie. 2009. http://www.cmq.org/. Accessed 15 novembre 2009. 
12. Barreau du Québec. Pour des soins de fin de vie respectueux des personnes. 
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Table 1: Relationship between descriptive classification and legal status of end-
of-life practices 
 
Descriptive classification of end-of-life practices  
Legal status of practices in selected jurisdictions 
Canada,  
United 
Kingdom, 
France, New 
Zealand 
Oregon, 
Washington, 
Vermont, 
Montana, 
Switzerland 
Belgium, 
Luxemburg 
Netherlands 
1. Witholding/withdrawal of  
life-sustaining treatment     
2. Use of drugs justified by  
symptoms management or  
treatment of a medical condition 
    
3. Intentional 
use of lethal 
drugs not 
justified by 
symptom 
management or 
treatment of a 
medical 
condition 
Self-administered  
by the patient, upon voluntary 
request  
    
Administered by professional 
with voluntary patient request 
or prior advanced directive of a 
previously competent patient 
    
Administered by professional to 
an incompetent patient with 
substituted request of a proxy 
decision-maker 
    
Table 1 legend: Yellow = authorized practices under restricted conditions; Red = prohibited 
practices. 
 
 
  
Table 2: Characteristics of all included studies on lethal drug use by physicians 
(n=333 articles) 
 
Year of publication N % 
<1990 1 0% 
1990-1994 19 0,06% 
1995-1999 62 0,18% 
2000-2004 82 0,24% 
2005-2009 107 0,32% 
2010-2012 66 0,20% 
Country 
  Netherlands 158 (47,4%)
Belgium 65 (19,5%) 
United States (other than Oregon) 40 (12,0%) 
Oregon 25 (7,5%) 
Scandinavia (Norway, Danemark, Sweden) 22 (6,6%) 
UK 17 (5,1%) 
Switzerland 16 (4,8%) 
Australia 15 (4,5%) 
France 5 (1,5%) 
Italy 5 (1,5%) 
Argentina 3 (0,9%) 
Germany 2 (0,6%) 
Japan 2 (0,6%) 
Spain 1 (0,3%) 
New Zealand 1 (0,3%) 
Austria 1 (0,3%) 
Bosnia 1 (0,3%) 
Luxembourg 1 (0,3%) 
Study design 
  Quantitative 248 (74,5%)
Qualitative 77 (23,1%) 
Systematic reviews 8 (2,4%) 
 
 
Table 3: Main objectives of all included studies on lethal drug use by physicians (n=333 articles) 
 
Themes N=number of articles 
(%)=percentage of 
articles Article focus/Main objective 
Determinants of the requests and practices of the use 
of a lethal drug 
64 (19,2%) 
The determinants of the 
requests and practices of 
euthanasia/assisted suicide. 
Medical end-of-life practices frequency* 
60 (18,0%) 
Data on the frequency of 
medical end-of-life practices. 
Medical end-of-life practices regulation and control 
mechanisms 
48 (14,4%) 
The consistency of medical end-
of-life practices with the 
existent standards and control 
mechanisms.  
Specific populations 29 (8,7%) 
The medical end-of-life 
practices among specific 
populations (elderly, new born, 
diagnostic, etc.) 
Nurse’s role 25 (7,5%) 
The nurse’s attitudes, practices 
and role in the use of lethal 
drugs and their involvement in 
the decision process and the 
care for patients that request 
and/or receive euthanasia.  
Assessment of use of lethal drug requests 15 (4,5%) 
Present data on health 
professional's assessment of 
the use of a lethal drug 
requests.  
Impacts on health professionals 13 (3,9%) 
The impacts (legal, emotional) 
of the requests and practices 
the use of a lethal drug on 
health professionals. 
Communication and consultations in the decision 
process of euthanasia 
12 (3,6%) 
The communications between 
the people involved in the end-
of-life decision process (patient, 
relatives, health professionals) 
including the consultation of 
outside expertise (consultants, 
experts). 
Impacts on patients and publics 9 (2,7%) 
Data on the impact of asking or 
being administered a lethal 
drug on the experience of death 
(death experience quality). 
Some articles in that thematic 
focus on the possible drifts and 
abuses or positive impacts on 
the public of legalizing 
euthanasia and assisted suicide. 
Impacts on relatives 8 (2,4%) 
Data on the impact of the use of 
lethal drugs on relative’s 
mental health and mourning 
process.   
Naming and labeling 7 (2,1%) 
How medical end-of-life 
practices are named and 
labeled within various 
populations and settings. 
Medical complications 6 (1,8%) 
Medical complications reported 
by health professionals with 
preparation and administration 
of a lethal drug. 
Psychiatric consultations and euthanasia 4 (1,2%) 
The value of a psychiatric 
consultation and of the 
involvement of a psychiatric 
expertise in the assessment of 
requests of the use of lethal 
drugs. 
Pharmacist’s practices 2 (0,6%) 
Data on the attitudes and 
practices of pharmacists 
regarding end-of-life medical 
practices. 
    
Note: *see Table 4 for detailed statistics on studies of medical end-of-life practice frequencies.
Table 4: Comparability of studies on the frequency of lethal drugs use by physicians  
(n=60 articles) 
 
Sampling method N (%) 
Sampling of all deaths 30 (50.0%) 
Sampling of professionals 30 (50.0%) 
Data collection method 
 Postal self-administered questionnaires 44 (73.3%) 
Interviews 13 (21.7%) 
Examination of medical records of reported cases  5(8.3%) 
Medical practice under study 
 Intentional use of lethal drugs by physicians 60 (100%) 
At the patient's request administered by the 
patient 47 (78.3%) 
At the patient's request administered by a health 
professional 49 (81.7%) 
Without the patient's request 35 (58.3%) 
Use drugs justified by symptom control 24 (40.0%) 
Withholding or withdrawal of medical treatment that 
has the potential to prolong life 29 (48.3%) 
Information on medical end-of-life practices   
Definition within article 41 (68.3%) 
Questions within article 46 (76.7%) 
Data on drug used 20 (33.3%) 
Data on dosage  6 (10.0%) 
Lethal potential as perceived by the clinician 19 (31.7%) 
Lethal potential as perceived by experts   5 (8.3%) 
Legislative context 
 Permissive policies  37 (61.7%) 
Restrictive policies  26 (43.3%) 
Comparaisons of end-of-life practices frequencies 
 
Before and after a change in public policy 16 (26.7%) 
Between jurisdictions with different public policies  17 (28.3%) 
 
 
 
 
Appendix 1: Search strategy 
 
 
Concepts  MEDLINE  Embase CINAHL 
#1 Intentional 
use of lethal 
drugs by 
physicians 
Euthanasia[MAJR:NOEXP] OR Euthanasia, 
active[MAJR:NOEXP] OR Euthanasia, Active, 
Voluntary[MAJR] OR Suicide, 
assisted[MAJR] OR Euthanasia*[TI] OR 
Assisted suicide[TI] OR Assisted 
suicides[TI] OR Assisted death[TI] OR 
Assisted deaths[TI] OR Assisted dying[TI] 
OR "Aid in dying" [TI] OR "End of life 
decision"[TI] OR "End of life 
decisions"[TI] OR "Termination of 
life"[TI] OR ((Medical behaviors[TI] or 
Medical behavior[TI] or Medical 
behaviour[TI] or Medical behaviours[TI]) 
AND (Shorten life[TI] or Shortens life[TI])) 
*Euthanasia/ or *Active euthanasia/ or 
*Voluntary euthanasia/ OR *Assisted 
suicide/ OR (Euthanasia* OR Assisted 
suicide OR Assisted suicides OR 
Assisted death OR Assisted deaths OR 
Assisted dying OR "End of life 
decision" OR "Aid in dying" OR "End of 
life decisions" OR "Termination of life" 
OR ((Medical behaviors or Medical 
behavior or Medical behaviour or 
Medical behaviours) AND (Shorten$ 
life or Shortens life))).ti 
MM "Euthanasia" OR TI 
(Euthanasia* OR Assisted suicide 
OR Assisted suicides OR Assisted 
death OR Assisted deaths OR 
Assisted dying OR "End of life 
decision" OR "End of life decisions" 
OR "Termination of life" OR 
((Medical behaviors or Medical 
behavior or Medical behaviour or 
Medical behaviours) AND 
(Shorten? life or Shortens life))) 
#2 Empirical 
studies 
"Data Collection"[MH:NOEXP] OR "Cross-
sectional studies"[MH] OR "Cohort 
studies"[MH] OR Questionnaires[MH] OR 
"Empirical Research"[MH] OR "Qualitative 
research"[MH] OR "Interviews as topic"[MH] 
OR Clinical Trial[PT] OR Comparative 
study[PT] OR Practice Guideline[PT] OR 
"Statistics and numerical data"[SH] OR 
(Data[TIAB] AND (Collected[TIAB] OR 
Colllection[TIAB] OR Collecting[TIAB])) OR 
Cross-sectional study[TIAB] OR Cohort[TIAB] 
OR Empirical Research[TIAB] OR Empirical 
Study[TIAB] OR Quantitative Research[TIAB] 
OR Quantitative Study[TIAB] OR Qualitative 
research[TIAB] OR Qualitative study[TIAB] 
OR Interview*[TIAB] OR 
Questionnaire*[TIAB] OR Survey[TIAB] OR 
Survey*[TIAB] OR Systematic review[TIAB] 
OR Clinical Trial[TIAB] OR Comparative 
study[TIAB] OR Practice guideline[TIAB] 
Data collection method/ OR Cross-
sectional study/ OR Cohort analysis/ OR 
Prospective study/ OR Retrospective 
study/ OR Exp Questionnaire/ OR 
Empirical Research/ OR Qualitative 
research/ OR Exp Interview/ OR 
Systematic review/ OR Exp Clinical Trial/ 
OR Comparative study/ OR Practice 
Guideline/ OR ((Data AND (Collected OR 
Colllection OR Collecting)) OR Cross-
sectional study OR Cohort OR Empirical 
Research OR Empirical Study OR 
Quantitative Research OR Quantitative 
Study OR Qualitative research OR 
Qualitative study OR Interview* OR 
Questionnaire* OR Survey* OR 
Systematic review OR Clinical Trial OR 
Comparative study OR Practice 
guideline).ti,ab 
MH "Data Collection" OR MH "Data 
Collection Methods+" OR MH "Cross 
Sectional Studies" OR MH 
"Prospective studies+" OR MH 
"Retrospective design" OR MH 
"Questionnaires+" OR MH "Empirical 
Research" OR MH "Qualitative 
Studies+" OR MH "Experimental 
studies+" OR MH "Systematic review" 
OR MH "Comparative studies" OR MH 
"Practice guidelines" OR TI ((Data AND 
(Collected OR Colllection OR 
Collecting)) OR Cross-sectional study 
OR Cohort OR Empirical Research OR 
Empirical Study OR Quantitative 
Research OR Quantitative Study OR 
Qualitative research OR Qualitative 
study OR Interview* OR 
Questionnaire* OR Survey* OR 
Systematic review OR Clinical Trial OR 
Comparative study OR Practice 
guideline) OR AB ((Data AND 
(Collected OR Colllection OR 
Collecting)) OR Cross-sectional study 
OR Cohort OR Empirical Research OR 
Empirical Study OR Quantitative 
Research OR Quantitative Study OR 
Qualitative research OR Qualitative 
study OR Interview* OR 
Questionnaire* OR Survey* OR 
Systematic review OR Clinical Trial OR 
Comparative study OR Practice 
guideline) 
#3 Has abstract Hasabstract Limité à Embase et Abstract Exclude Medline et Abstract 
#4 Humans Animals[MH] NOT Humans[MH] (Animals/ OR Nonhuman/) NOT Human/ MH "Animals+" NOT MH "Humans" 
# Combine (#1 AND #2 AND #3) NOT #4 (#1 AND #2 AND #3) NOT #4 (#1 AND #2 AND #3) NOT #4 
 
